Clinigen Group plc Issue of Equity (9810M)

TIDMCLIN

RNS Number : 9810M

Clinigen Group plc

21 October 2016

21 October 2016

Issue of Equity

Clinigen Group plc (the "Group", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 388,771 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 24 October 2016.

At admission the issued share capital of the Group will consist of 115,094,263 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 115,094,263. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interest in, the Group under the Disclosure and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                  Tel: [phone] 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer-designate 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 Peel Hunt LLP                       Tel: +44 (0) 20 
                                      7418 8900 
 James Steel / Dr Christopher 
  Golden 
 
 Instinctif Partners                 Tel: +44 (0) 20 
                                      7457 2020 
 Adrian Duffield / Melanie 
  Toyne-Sewell / Jayne Crook         Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEFFLFLUFMSEES

(END) Dow Jones Newswires

October 21, 2016 03:00 ET (07:00 GMT)